Everest Medicines Licensing Partner Pfizer Reports the US FDA and EMA’s Acceptance of NDA and MAA for Etrasimod in Ulcerative Colitis
- The US FDA has accepted an NDA for review of etrasimod & EMA also accepted the MAA for active UC. The US FDA & EMA decision are expected in H2’23 & H1’24
- The submissions were based on the P-III (ELEVATE UC 52 & 12) trials evaluating etrasimod (2mg, qd) vs PBO. Both trials met their 1EPs & 2EPs i.e., clinical remission (27.0% & 24.8% vs 7.4% & 15.2%) @12wks.; 32.1% vs 6.7% @52wk. in (ELEVATE UC 52) along with corticosteroid-free remission & sustained clinical remission @52wk.
- Improvements in 2EPs incl. endoscopic improvement, symptomatic remission & mucosal healing @12 & 52wk. in (ELEVATE UC 52) & @12wk. in (ELEVATE UC 12) & the safety profile was consistent with prior studies. In (ELEVATE UC 12), similar patients experienced TEAEs while in (ELEVATE UC 52) it was higher in etrasimod
Ref: Business Wire | Image: Pfizer
Realted Posts:- Everest Licensing Partner Pfizer Presents Results of Etrasimod in P-III (ELEVATE UC 12 & 52) Studies for the Treatment of Ulcerative Colitis at DDW 2022
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected]